Bell Potter names the best ASX healthcare stocks to buy in FY25
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below.
They have just been tipped as Bell Potter's top healthcare stocks to buy now:
Aroa Biosurgery Ltd (ASX: ARX)
Aroa Biosurgery describes itself as a soft-tissue regeneration company committed to unlocking regenerative healing for everybody.
Bell Potter is feeling very positive about the company's outlook and has put a buy rating and 90 cents price target on its shares. It is expecting the ASX healthcare stock's strong top line growth to continue in FY 2025 and FY 2026. It said:
In FY24 revenues grew by 75% to NZ$23.3m and we expect a similar growth rate in FY25 and FY26 driven by an expanded user base and data from the Myriad Augmented Soft Tissue Regeneration Registry (MASTRR). ARX also expects to report data from its 120 patient randomised clinical trial in diabetic foot ulcer patients. The trial is investigating the healing properties of the Symphony product. Earlier studies in a very difficult patient population with advanced DFU's provided highly supportive data on the rate of wound healing.
Cyclopharm Ltd (ASX: CYC)
Bell Potter is also bullish on this global radiopharmaceutical company which has a focus on pulmonary care. Especially given its strong balance sheet following a recent capital raising.
The broker currently has a buy rating and $3.40 price target on the ASX healthcare stock. It said:
Cyclopharm recently completed a $24m capital raise with funds to provide working capital to support the expanding revenue base in the US. Since receiving FDA approval for Technegas in the US in September 2023, CYC has notched up numerous firsts including contract signings and first revenues earned. [â¦] The company estimates the US market for Technegas at US$180m annually inclusive of US$90m being the initial market for diagnosis of pulmonary embolism (PE) which it believes it can win within 5 to 7 years from launch. The second stage of the market also relates to PE where the company believes it can win market share in those patients currently diagnosed via CT.
Telix Pharmaceuticals Ltd (ASX: TLX)
Finally, another radiopharmaceutical company that could be a buy according to Bell Potter is Telix. It has a buy rating and $19.00 price target on its shares.
Bell Potter likes the company due to its revenue-generating Illuccix product, as well as its promising product pipeline. The broker explains:
The fundamental drivers of value remain firmly in place, including: revenues from the sale of Illuccix continue to grow; recently completed submission of the Biological license application for Zircaix in early June; and additional catalysts including submission of the New Drug Application for Pixclara, commencement of enrolment in the prostate cancer therapy and initial data from the STARLITE trial.
Should you invest $1,000 in Aroa Biosurgery Limited right now?
Before you buy Aroa Biosurgery Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Aroa Biosurgery Limited wasn't one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys...
See The 5 Stocks *Returns as of 24 June 2024
More reading
Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.